[
    "{\"step_by_step_thinking\": \"Based on the provided documents, there is evidence that tremelimumab, when used alone or in combination with other drugs, has shown activity and a good safety profile in patients with mesothelioma. In Document [0], a phase 2 trial showed that tremelimumab combined with durvalumab resulted in an immune-related objective response in 28% of patients and a median overall survival of 16.6 months. Document [1] reported 4-year survival outcomes after retreatment with tremelimumab, and Document [3] described the efficacy and safety of an intensified schedule of tremelimumab. However, it is important to note that Document [2] mentioned that tremelimumab failed to improve lifespan in a phase IIb trial. Overall, based on the available evidence, the answer is A. yes, tremelimumab can improve survival of mesothelioma patients.\", \"answer_choice\": \"A\"}"
]